A new research collaboration aims to develop a test to identify Alzheimer’s sufferers early on, potentially before they start showing any symptoms of the condition.
Nestlé Institute of Health Sciences (NIHS) has entered into an agreement with biopharmaceutical company AC Immune to develop a new, minimally invasive method of diagnosing Alzheimer’s disease in its initial stages.
Through the partnership, scientists will use exclusive NIHS technology that can measure certain biomarkers in the blood associated with cognitive decline.
Finding an effective test to diagnose Alzheimer’s in its very early stages is considered to be one of the most pressing needs in the treatment of the disease.
Read the Nestlé Institute of Health Sciences press release.